Biocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals.

Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...